Imeglimin
Imeglimin is an experimental drug candidate for the treatment of Type 2 diabetes. It is being developed by Poxel and Sumitomo Dainippon Pharma. Imeglimin works by targeting the mitochondria to enhance glucose-stimulated insulin secretion and insulin sensitivity, and to preserve beta cell mass and function.
Mechanism of action[edit | edit source]
Imeglimin's mechanism of action is unique and it acts on three main target organs involved in glucose regulation: the liver, muscle, and the pancreas. It is the first clinical candidate in a new class of oral anti-diabetic agents, the Glimins. Imeglimin acts on the mitochondria and specifically improves bioenergetics. It enhances glucose-stimulated insulin secretion and insulin sensitivity, and it preserves beta cell mass and function, which allows for sustained glucose lowering effects.
Clinical trials[edit | edit source]
Imeglimin has completed Phase 1 and Phase 2 development in over 1,200 subjects in the U.S., EU and Japan. In the U.S. and EU, Imeglimin has successfully completed Phase 2 development in over 850 patients. In Japan, Imeglimin has completed a Phase 2b clinical trial in 299 treatment-naïve patients and a Phase 3 program is currently ongoing.
References[edit | edit source]
See also[edit | edit source]
Imeglimin Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD